Mylan Defeats Teva's Motion for Summary Judgment on Copaxone; Court Orders Trial on Inequitable Conduct Defense to Commence July

PITTSBURGH, June 17, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the U.S. District Court for the Southern District of New York has denied Teva's motion for a summary judgment finding of no inequitable conduct in relation to Copaxone®.  

In addition, the court set a start date of July 11, 2011, for the trial regarding Mylan's inequitable conduct affirmative defense. The remaining issues will be tried beginning on Sept. 7, 2011.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

SOURCE Mylan Inc.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.